Since both KV1.3 (Beeton et al., 2006; Pereira et al., 2007) and KCa3.1 (Ataga et al., 2008; Maezawa et al., 2012) blockers have been shown to be relatively safe and well tolerated in vivo we would like to suggest KV1.3 and KCa3.1 inhibition as pharmacological approaches to preferentially inhibit detrimental microglia responses in stroke and other brain disorders associated with neuroinflammation (Dale et al., 2016). The gene discussed is KCNA3; the disease is stroke disorder.